EIDD-1931 Oral Capsules

Description

MolnuFIP™ delivers pure EIDD-1931, the active antiviral metabolite of molnupiravir, in a formulation designed exclusively for feline physiology. By using EIDD-1931 directly—rather than modifying human molnupiravir capsules—MolnuFIP™ provides a more precise, consistent, and veterinary-appropriate approach to FIP care.

Purpose-Built Feline Formulation

Each MolnuFIP™ EIDD-1931 capsule contains 15 mg of EIDD-1931, equivalent in activity to approximately 66 mg of molnupiravir (EIDD-2801).

This formulation is optimized for:

Feline metabolic rate
Gastrointestinal absorption profile
Reliable dose–response performance

The result is accurate, predictable antiviral activity with reduced variability compared to human-intended products.

Proven Antiviral Potency

Published research demonstrates that:

EIDD-1931 exhibits up to 10× greater in-vitro antiviral potency compared with molnupiravir (EIDD-2801).
EIDD-1931 demonstrates 7.3× higher potency than GS-441524 under similar test conditions.

This potency advantage enables therapeutic efficacy at lower milligram doses, supporting improved tolerability and rapid clinical response.

Reference:

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity Against Enterovirus Infections In Vitro and In Vivo

https://www.mdpi.com/1999-4915/14/6/1142

Comprehensive Support Across FIP Presentations

MolnuFIP™ is formulated to support recovery across all major forms of FIP, including:

Wet FIP (effusive)
Dry FIP (non-effusive)
Mixed or transitional presentations

Additional formulation benefits:

Optimized for feline metabolism and tissue penetration
Highly consistent blood-level performance
Designed to support low relapse incidence when used according to veterinary guidance

Precision, Safety & Confidence in Every Dose

With MolnuFIP™, your cat receives an advanced, veterinary-engineered antiviral designed for dependable performance:

Scientifically grounded formulation
Consistent mg-per-kg dosing
No need to modify human medications
Backed by modern antiviral research

Visit molnufip.com for more information

Dosage Instruction

Dosage Instructions

Administer one (1) capsule per 2.5 kg of body weight, given every 12 hours.

Dosing Examples

• Example 1: A 2.0 kg kitten diagnosed with the effusive (wet) form of FIP should receive one capsule every 12 hours.

• Example 2: A 4.6 kg adult cat diagnosed with the non-effusive (dry) form of FIP should receive two capsules every 12 hours.

Monitoring and Follow-Up

We strongly recommend that your cat receives a complete blood panel approximately every 30 days, in conjunction with ongoing evaluation by your primary veterinarian. Regular monitoring allows your veterinarian to assess clinical response and determine whether continued treatment, dose adjustment, or discontinuation is appropriate.

Product Description

Active Ingredient: EIDD-1931

Inactive Ingredient: Dibasic Calcium Phosphate, Magnesium Sterate

Form: Size #3 Capsules

Indications: Ideal for felines with effusive (wet) and non-effusive (dry) feline infectious peritonitis (FIP)

Specification: 60 capsules, each containing 15 mg of EIDD-1931

Dosage: 1 capsule every 12 hours for every 2.5 kg of body weight, preferably on an empty stomach.

If vomiting occurs within 30 minutes, administer another capsule.

Not Recommended Use:

Ocular or neurological FIP cases.
Cats not feeding or defecating normally
Cats with a history of poor dietary absorption.

Length of Treatment: Up to 60 days or as recommended by a veterinarian.

Storage: Store in a dry, cool place away from sunlight.

Packaging:
Each pack contains 60 capsules in vacuum-sealed mylar bag.
For cats weighing up to 2.5kg package use 60 capsules every 30 days.
For cats weighing 2.5 to 5kg package use 120 capsules every 30 days.
For cats weighing above 5kg package contains 180 capsules every 30 days.

Expiration: 12 months

Reviews

There are no reviews yet.

Be the first to review “EIDD-1931 Oral Capsules”